Cue Health (Nasdaq: HLTH) is a healthcare technology company that puts consumers in control of their health information and places diagnostic information at the center of care.
Cue Health enables people to manage their health through real-time, actionable, and connected health information, offering individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. Cue Health’s first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision.
Outside the United States, Cue Health has received the CE mark in the European Union, Interim Order authorization from Health Canada, and regulatory approval from India’s Central Drugs Standard Control Organisation.
Cue was founded in 2010 and is headquartered in San Diego. For more information, please visit www.cuehealth.com.
SAN DIEGO--(BUSINESS WIRE)--Jan. 11, 2022-- Cue Health Inc. (Nasdaq: HLTH), a healthcare technology company, (“Cue’) today reported preliminary unaudited revenue for fourth quarter and full year 2021. Preliminary Fourth Quarter and Full Y...
Cue Health to Develop Omicron-Genotyping COVID-19 Test in Partnership with the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA)
Jan 06, 2022
New test will provide clinicians and researchers with advanced health information to enable better-informed treatment and containment decisions in real-time SAN DIEGO, Jan. 6, 2022 /PRNewswire/ -- Cue Health ("Cue") (Nasdaq: HLTH), a healthcar...
SAN DIEGO--(BUSINESS WIRE)--Jan. 5, 2022-- Cue Health (“Cue”) (Nasdaq:HLTH), a healthcare technology company, announced today that its management team will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11,...